Roche (ROG: SIX) was one of the worst hit by pledges made by US President Donald Trump on Medicare drug prices on Thursday.
The Swiss pharma giant closed 4% down following the proposals for a new Medicare model using the international pricing index (IPI).
Mr Trump and Alex Azar, Secretary for Health and Human Services, unveiled plans that they said would cut down on “foreign freeloading” and reduce US drug prices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze